Rezafungin acetate

醋酸瑞扎芬净

Report date: 2026/03/31 20:00:21
NMEQIDP

Base Information

Drug NameRezafungin acetate
Drug Alias Name雷扎芬净Biafungin acetateRezafunginTopifunginRezafungin acetate +[11] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of Action1,3-beta-glucan synthase inhibitors
Targets1,3-beta-glucan synthase
Therapy Area/IndicationsSepsisPneumocystis InfectionsFungemia +[11] 
Global Approved IndicationsCandidemiaCandidiasis, InvasiveCandidiasis
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2023/03/22
Country/TerritoryBelgiumBulgariaCanada +[27] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaNDA/BLA
Originator CompaniesSeachaid Pharmaceuticals
China Registration ClassN/A

Develop Information

Active CompaniesMundipharma Research LtdMundipharma Corporation (Ireland) LtdCidara Therapeutics Inc +[4] 
Inactive CompaniesMelinta Therapeutics LLCNational Institute Of Allergy And Infectious Diseases (Niaid)
Active IndicationsPneumocystis InfectionsFungemiaInvasive Fungal Infections +[9] 
Inactive IndicationsSepsisCandidiasis, Vulvovaginal

Other Information

ATC CodeJ02AX08
Related LinksDrugBankKEGG